No association of HMOX1 and UGT1A1 gene variants was found for any of the various laboratory markers tested (Tables S1 and S2), the stage of liver fibrosis, or the presence of NASH (data not shown), thus indicating a negligible role of these polymorphisms on the clinical status of NAFLD patients. This evidence concerns the gene UGT1A1 and metabolic dysfunction-associated steatotic liver disease.